Advertisement

Citations to this article

Abstract

Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced productivity in the drug industry is caused mainly by corporate policies that discourage innovation. This is compounded by various consequences of mega-mergers, the obsession for blockbuster drugs, the shift of control of research from scientists to marketers, the need for fast sales growth, and the discontinuation of development compounds for nontechnical reasons. Lessons from the past indicate that these problems can be overcome, and herein, new and improved directions for drug discovery are suggested.

Authors

Pedro Cuatrecasas

×

Total citations by year

Year: 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 9 7 17 9 9 15 14 10 90
Citation information

Citations to this article in year 2008 (14)

Title and authors Publication Year
Opportunities and Challenges in the Discovery of New Central Nervous System Drugs
JE Krause, BL Chenard
Annals of the New York Academy of Sciences 2008
Drug absorption modeling as a tool to define the strategy in clinical formulation development
M Kuentz
The AAPS Journal 2008
Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?
JP Ioannidis
Philosophy, ethics, and humanities in medicine : PEHM 2008
Drug discovery paradigms: past, present, future – a centennial symposium of the American Society for Pharmacology and Experimental Therapeutics
I Cavero, HR Kaplan
Expert Opinion on Drug Discovery 2008
The significance of non-human primates as preclinical models of human arthritic disease
M Vierboom, E Breedveld, I Kondova, BA Hart
Expert Opinion on Drug Discovery 2008
Systems Biology
RL Ho, CA Lieu
Drugs in R & D 2008
Application of LC/MS and related techniques to high-throughput drug discovery
A Espada, M Molina-Martin, J Dage, MS Kuo
Drug Discovery Today 2008
Managing freedom: Managing researchers as if they were warriors
J Uitdehaag
Drug Discovery Today 2008
Needed: system dynamics for the drug discovery process
S Sirois, LM Cloutier
Drug Discovery Today 2008
Metabolomics and biomarker discovery: NMR spectral data of urine and hepatotoxicity by carbon tetrachloride, acetaminophen, and d-galactosamine in rats
KB Kim, MW Chung, SY Um, JS Oh, SH Kim, MA Na, HY Oh, WS Cho, KH Choi
Metabolomics 2008
A ‘BOLD’ experiment in defining the utility of fMRI in drug development
D Borsook, D Bleakman, R Hargreaves, J Upadhyay, KF Schmidt, L Becerra
NeuroImage 2008
Evolution in thinking and processes?
A Sewing
Drug Discovery Today: Technologies 2008
Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement
I Chopra, C Schofield, M Everett, A O'Neill, K Miller, M Wilcox, JM Frère, M Dawson, L Czaplewski, U Urleb, P Courvalin
The Lancet Infectious Diseases 2008
Zebrafish assays as early safety pharmacology screens: Paradigm shift or red herring?
WS Redfern, G Waldron, MJ Winter, P Butler, M Holbrook, R Wallis, JP Valentin
Journal of Pharmacological and Toxicological Methods 2008

Advertisement
Advertisement